Matthew G. Hurd
Lawdragon 500
Sullivan & Cromwell LLP
125 Broad Street
New York, NY 10004
212-558-4000(direct)
212-558-4000 (firm)
212-558-3588 (firm fax)
http://www.sullcrom.com
Contact
PROFILE
Matthew G. Hurd advises domestic and international clients on mergers, acquisitions and complex investment transactions. He has extensive experience with healthcare clients and financial institutions.
For almost 20 years Mr. Hurd has been actively involved in the development of the Firm’s Healthcare and Life Sciences practice, of which is Co-Head. In 2011, Mr. Hurd acted for the target company in both the first and second largest healthcare mergers in North America, namely:
- Medco, North America’s leading pharmacy benefits management provider, in its $34.3 billion acquisition by Express Scripts, and
- Pharmasset, an 80-employee clinical stage pharmaceutical company, in its $11 billion acquisition by Gilead – a transaction for which Mr. Hurd was recently named The American Lawyer’s “Dealmaker of the Week.”
In Pharmaceuticals, he represents a major global pharmaceutical company on acquisition projects, and advises a leading U.S. specialty pharmaceutical company concerning various strategic transactions. Previously, he represented a number of family-owned drug companies in their sale to global pharmaceutical companies, and represented Pharmacia and its predecessor companies in each major change in control transaction prior to the transaction in which Pfizer acquired Pharmacia. In Biotech, Mr. Hurd regularly represents Amgen, the world’s largest biotech company, in its acquisitions of public and venture-backed biotech companies such as Abgenix, Avidia and Ilypsa, as well as its joint venture with Kirin. In Medical Devices, Mr. Hurd has represented Philips Electronics in the largest acquisitions in its corporate history, which transformed Philips Healthcare into the second largest medical device company in the world.
Mr. Hurd has also been associated with aspects of the Firm’s Financial Institutions practice throughout his career. In 2010, he led the negotiations in four transactions involving The Royal Bank of Scotland’s divestiture of a sizable Latin American loan book and its subsidiary banks in each of Argentina, Chile and Colombia. He has previously represented UBS, Europe’s largest bank, in its acquisitions of various private banking and specialty businesses in North America, regularly represents Fiserv in acquisitions and divestitures of significant businesses, including its recent acquisitions of CashEdge and CheckFree.
Mr. Hurd has particular expertise with Distressed Businesses. He was deeply involved in the Firm’s representation of Carter-Wallace, which involved an at-market breakup of a public company, and Adelphia, which involved the largest sale of a bankrupt corporation in U.S. history. During the financial calamity of 2008, he represented Mitsubishi UFJ in connection with its equity investment in Morgan Stanley, and the distressed ABC Learning Centres in connection with its rescue by funds associated with Morgan Stanley Private Equity. Since 2008, he has advised various clients in the acquisition or potential acquisition of troubled businesses or assets.
Mr. Hurd was actively involved in developing the Firm’s Technology practice and during the technology boom co-founded the Firm’s Silicon Valley office in California. Since his return to New York, he and another partner have mentored several classes of beginning corporate lawyers as they progress through Sullivan & Cromwell’s rigorous eighteen-month initial associate development program. Mr. Hurd speaks regularly at professional gatherings associated with mergers and acquisitions. His charitable and cultural interests include service on the board of the Metropolitan Opera.
Recognitions
- Featured in Law360’s Healthcare and Life Sciences Q&A (July 2012)
- Profiled in Practical Law The Journal’s “Expert’s View” column (February 2012) on trends and developments in public M&A deals
- Named “Dealmaker of the Week” (November 23, 2011) by The American Lawyer for his role as counsel to Pharmasset in its acquisition by Gilead Sciences
- Recognized as one of the Lawdragon 500 Leading Lawyers in America (2011)
- The Best Lawyers in America – recognized as a leading lawyer in mergers and acquisitions (2007, 2008, 2009, 2010, 2011, 2012, 2013)
Education
- 1991, UC Berkeley School of Law, J.D.
- 1988, University of California, Los Angeles, B.A.
Bar Admissions
- California
- New York
See Library Tab for articles, publications and presentations by Matthew Hurd
LIBRARY
News
-
Law360 Interview Highlights Matt Hurd’s Healthcare Practice
July 16, 2012 -
Matt Hurd Profiled in Practical Law The Journal Expert’s View Q&A on Trends and Developments in Public M&A Deals
February 2012 -
Healthcare and Life Sciences Group Mergers & Acquisitions 2011 Year in Review Brochure
February 2012 -
S&C Recognized Among mergermarket and Financial Times’ Americas’ M&A Awards 2011
January 10, 2012 -
The Am Law Daily Names Matt Hurd Dealmaker of the Week
November 23, 2011
Events & Speaking Engagements
Q&A
LOCATION
EDITORIAL REVIEW
Sullivan’s healthcare and life sciences co-leader represented Pharmasset in its $11B acquisition by Gilead, and Medco in its $34B purchase by Express Scripts – the two largest M&As in the healthcare arena.
Contact Lawdragon about the information in this review.
EVALUATION
Fill in the requested information below, then submit your evaluation to have your scores calculated as part of Matthew G. Hurd Lawdragon ranking.By submitting this form, you agree to Lawdragon's TERM OF USE.
